TD Asset Management
PCVX icon

TD Asset Management’s Vaxcyte PCVX Stock Holding History

TD Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Sell
274,640
-38,122
-12% -$2.07M 0.01% 554
2026
Q1 		$18.2M Sell
312,762
-50,972
-14% -$2.77M 0.01% 530
2025
Q4 		$16.8M Sell
363,734
-34,746
-9% -$1.55M 0.01% 540
2025
Q3 		$14.4M Sell
398,480
-141,304
-26% -$4.68M 0.01% 571
2025
Q2 		$17.5M Buy
539,784
+236,188
+78% +$7.74M 0.02% 518
2025
Q1 		$11.5M Sell
303,596
-30,160
-9% -$2.41M 0.01% 607
2024
Q4 		$27.3M Sell
333,756
-32,400
-9% -$3.22M 0.02% 436
2024
Q3 		$41.4M Buy
366,156
+53,730
+17% +$4.84M 0.04% 340
2024
Q2 		$23.6M Buy
312,426
+31,138
+11% +$2.12M 0.02% 451
2024
Q1 		$19.2M Buy
281,288
+114,252
+68% +$7.91M 0.02% 498
2023
Q4 		$10.5M Buy
167,036
+15,890
+11% +$825K 0.01% 608
2023
Q3 		$7.71M Buy
151,146
+62,101
+70% +$3.06M 0.01% 633
2023
Q2 		$4.45M Buy
89,045
+69,845
+364% +$3.31M 0.01% 766
2023
Q1 		$720K Buy
19,200
+5,644
+42% +$239K ﹤0.01% 1201
2022
Q4 		$650K Buy
+13,556
New +$532K ﹤0.01% 1230

Other funds holding PCVX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TD Asset Management's PCVX Position: Q2 2026 in Review

TD Asset Management reduced its Vaxcyte (PCVX) stake by 12% in Q2 2026, selling an estimated $2.07M and leaving 274,640 shares worth $16M. The position accounts for 0.01% of the portfolio, ranked #554.

TD Asset Management first reported a position in PCVX in Q4 2022 and has held it in 15 quarters since. The position peaked at $41.4M in Q3 2024. 222 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • TD Asset Management held 274,640 shares of Vaxcyte worth $16M as of Q2 2026.
  • TD Asset Management sold 38,122 Vaxcyte shares in Q2 2026, an estimated $2.07M.
  • Vaxcyte made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #554 holding.
  • TD Asset Management first reported a position in Vaxcyte in Q4 2022 and has held it in 15 quarters since.
  • TD Asset Management's Vaxcyte position peaked at $41.4M in Q3 2024.
  • 222 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.